Centre for Trauma Sciences, Blizard Institute, Queen Mary University of London, UK.
Academic Department of Military Surgery and Trauma, Research and Clinical Innovation, Birmingham.
Curr Opin Crit Care. 2023 Dec 1;29(6):689-695. doi: 10.1097/MCC.0000000000001106. Epub 2023 Sep 28.
The use of Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA) to temporarily control bleeding and improve central perfusion in critically injured trauma patients remains a controversial topic. In the last decade, select trauma services around the world have gained experience with REBOA. We discuss the recent observational data together with the initial results of the first randomized control trial and provide a view on the next steps for REBOA in trauma resuscitation.
While the observational data continue to be conflicting, the first randomized control trial signals that in the UK, in-hospital REBOA is associated with harm. Likely a result of delays to haemorrhage control, views are again split on whether to abandon complex interventions in bleeding trauma patients and to only prioritize transfer to the operating room or to push REBOA earlier into the post injury phase, recognizing that some patients will not survive without intervention.
Better understanding of cardiac shock physiology provides a new lens in which to evaluate REBOA through. Patient selection remains a huge challenge. Invasive blood pressure monitoring, combined with machine learning aided decision support may assist clinicians and their patients in the future. The use of REBOA should not delay definitive haemorrhage control in those patients without impending cardiac arrest.
使用主动脉腔内球囊阻断复苏术(REBOA)暂时控制出血并改善严重创伤患者的中心灌注仍然是一个有争议的话题。在过去的十年中,世界各地的一些创伤服务机构已经积累了 REBOA 的经验。我们讨论了最近的观察性数据以及首个随机对照试验的初步结果,并对创伤复苏中 REBOA 的下一步发展提出了看法。
虽然观察性数据仍然存在争议,但首个随机对照试验表明,在英国,院内 REBOA 与危害相关。可能是由于出血控制延迟的结果,对于是否放弃对出血性创伤患者的复杂干预,以及是否仅优先将其转至手术室,或者更早地将 REBOA 推进到损伤后阶段,人们的观点再次出现分歧,因为如果不进行干预,一些患者将无法存活。
对心脏休克生理学的更好理解为评估 REBOA 提供了一个新的视角。患者选择仍然是一个巨大的挑战。有创血压监测,结合机器学习辅助决策支持,可能有助于未来的临床医生及其患者。对于那些没有即将发生心脏骤停的患者,不应因使用 REBOA 而延迟明确的出血控制。